Literature DB >> 25973063

Modulation of the function of dendritic cells in adolescents with chronic HBV infection by IFN-λ1.

Haihua Sun1, Lijuan Bi1, Junying Zhou1, Dongfang Zhou1, Yinghui Liu1, Guohua Jin1, Wenzhao Yan1.   

Abstract

The exact immunology pathogenesis of hepatitis B virus (HBV) infection remains unclear currently. The dendritic cells (DCs) dysfunction is evident in adolescents with chronic HBV infection in the immune tolerant phase. DCs, as the most efficient professional antigen-presenting cells (APCs), possess the strongest antigen presenting the effect in the body and can stimulate the initial T cell activation and proliferation, depending on their stage of maturation. The recently classified type III interferon group, interferon-λ1 (IL-29), interferon-λ2 (IL-28A), and interferon-λ3 (IL-28B) displays immunomodulatory and antiviral activity. In the current study, we describe a way to stimulate the DCs maturation. As a result, IFN-λ1 combined with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) and recombinant human interleukin-4 (rhIL-4) can induce the DCs maturation and promote the costimulatory molecules such as CD80, CD83, CD86 and human leucocyte antigen DR (HLA-DR) expression in the immune tolerance and the clearance phases. This study demonstrates that the DCs function is remarkably impaired both in the immune tolerant phase and the immune clearance phase in adolescents with chronic HBV infection compared with healthy youth control. At the same time, this study has developed a theoretical basis for the application of IFN-λ1 breaking immune tolerance and improving the body's immune system to clear HBV.

Entities:  

Keywords:  Dendritic cells; adolescents; hepatitis B; immune tolerance; interferon-λ1

Mesh:

Substances:

Year:  2015        PMID: 25973063      PMCID: PMC4396338     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  36 in total

Review 1.  Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity.

Authors:  Y J Liu
Journal:  Cell       Date:  2001-08-10       Impact factor: 41.582

2.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

3.  Increased infiltration of intrahepatic DC subsets closely correlate with viral control and liver injury in immune active pediatric patients with chronic hepatitis B.

Authors:  Zheng Zhang; Dawei Chen; Jinxia Yao; Hui Zhang; Lei Jin; Ming Shi; Hongfei Zhang; Fu-Sheng Wang
Journal:  Clin Immunol       Date:  2006-10-18       Impact factor: 3.969

Review 4.  IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties.

Authors:  Katrin Witte; Ellen Witte; Robert Sabat; Kerstin Wolk
Journal:  Cytokine Growth Factor Rev       Date:  2010-07-23       Impact factor: 7.638

5.  Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus.

Authors:  Sachiyo Yoshio; Tatsuya Kanto; Shoko Kuroda; Tokuhiro Matsubara; Koyo Higashitani; Naruyasu Kakita; Hisashi Ishida; Naoki Hiramatsu; Hiroaki Nagano; Masaya Sugiyama; Kazumoto Murata; Takasuke Fukuhara; Yoshiharu Matsuura; Norio Hayashi; Masashi Mizokami; Tetsuo Takehara
Journal:  Hepatology       Date:  2013-03-14       Impact factor: 17.425

6.  Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B.

Authors:  Renate G van der Molen; Dave Sprengers; Rekha S Binda; Esther C de Jong; Hubert G M Niesters; Johannes G Kusters; Jaap Kwekkeboom; Harry L A Janssen
Journal:  Hepatology       Date:  2004-09       Impact factor: 17.425

7.  GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells.

Authors:  C Caux; C Dezutter-Dambuyant; D Schmitt; J Banchereau
Journal:  Nature       Date:  1992-11-19       Impact factor: 49.962

8.  Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29).

Authors:  Nicholas J Megjugorac; Grant E Gallagher; Grant Gallagher
Journal:  J Leukoc Biol       Date:  2009-09-16       Impact factor: 4.962

Review 9.  Natural history of chronic hepatitis B virus infection and long-term outcome under treatment.

Authors:  Yun-Fan Liaw
Journal:  Liver Int       Date:  2009-01       Impact factor: 5.828

10.  Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent.

Authors:  Philippa Hillyer; Viraj P Mane; Lynnsie M Schramm; Montserrat Puig; Daniela Verthelyi; Aaron Chen; Zeng Zhao; Maria B Navarro; Kevin D Kirschman; Srikant Bykadi; Ronald G Jubin; Ronald L Rabin
Journal:  Immunol Cell Biol       Date:  2012-01-17       Impact factor: 5.126

View more
  4 in total

1.  Enrichment of Ly6Chi monocytes by multiple GM-CSF injections with HBV vaccine contributes to viral clearance in a HBV mouse model.

Authors:  Weidong Zhao; Xian Zhou; Gan Zhao; Qing Lin; Xianzheng Wang; Xueping Yu; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2017-07-12       Impact factor: 3.452

2.  Enhanced serum interferon-lambda 1 interleukin-29 levels in patients with psoriasis vulgaris.

Authors:  Li-Xin Fu; Tao Chen; Zai-Pei Guo; Na Cao; Li-Wen Zhang; Pei-Mei Zhou
Journal:  An Bras Dermatol       Date:  2021-05-24       Impact factor: 1.896

Review 3.  Clinical Implications of Hepatitis B Virus RNA and Covalently Closed Circular DNA in Monitoring Patients with Chronic Hepatitis B Today with a Gaze into the Future: The Field Is Unprepared for a Sterilizing Cure.

Authors:  Anastasiya Kostyusheva; Dmitry Kostyushev; Sergey Brezgin; Elena Volchkova; Vladimir Chulanov
Journal:  Genes (Basel)       Date:  2018-10-05       Impact factor: 4.096

4.  Clearance of HBeAg and HBsAg of HBV in mice model by a recombinant HBV vaccine combined with GM-CSF and IFN-α as an effective therapeutic vaccine adjuvant.

Authors:  Weidong Zhao; Gan Zhao; Shuren Zhang; Xianzheng Wang; Xueping Yu; Bin Wang
Journal:  Oncotarget       Date:  2018-07-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.